semaglutide and methylphenidate Semaglutide, a novel glucagon-like peptide-1

This has exciting, broad implications for all of these [specialties]. References: American Diabetes Association Professional Practice Committee

Fatigue and constipation are commonly reported, along with nausea during dose escalation

The GLP-1RA liraglutide has also been approved for the treatment of obesity at a higher standard dose (3 mg once daily) compared to the standard dose used for T2D treatment (1.2 mg once daily) due to the results of the SCALE study program (37, 38)

[1] [2] Yes, tirzepatide can cause nausea and vomiting , and these are among the most frequently reported gastrointestinal side effects associated with this medication

Specific, research-backed causes with equally specific solutions

Severe gastroparesis or other serious GI motility disorders make tirzepatide problematic